![Anat Kerem-Angel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historial de carrera de Anat Kerem-Angel
Antiguos cargos conocidos de Anat Kerem-Angel.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Youdim Pharmaceuticals Ltd.
![]() Youdim Pharmaceuticals Ltd. Investment ManagersFinance Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel. | Inversor de Capital Privado | 01/01/2004 | 31/12/2010 |
Thrombotech Ltd.
![]() Thrombotech Ltd. Medical SpecialtiesHealth Technology Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel. | Director/Miembro de la Junta | - | - |
Formación de Anat Kerem-Angel.
Tel-Aviv University | Doctorate Degree |
Estadísticas
Internacional
Israel | 4 |
Operativa
Private Equity Investor | 1 |
Director/Board Member | 1 |
Doctorate Degree | 1 |
Sectorial
Finance | 2 |
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Youdim Pharmaceuticals Ltd.
![]() Youdim Pharmaceuticals Ltd. Investment ManagersFinance Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel. | Finance |
Thrombotech Ltd.
![]() Thrombotech Ltd. Medical SpecialtiesHealth Technology Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel. | Health Technology |
- Bolsa de valores
- Insiders
- Anat Kerem-Angel
- Experiencia